RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+4.61%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$870M
AUM Growth
-$103M
(-11%)
Cap. Flow
-$107M
Cap. Flow
% of AUM
-12.27%
Top 10 Holdings %
Top 10 Hldgs %
34.33%
Holding
104
New
12
Increased
20
Reduced
55
Closed
10
Top Buys
| 1 |
Glaukos
GKOS
|
$23M |
| 2 |
Bristol-Myers Squibb
BMY
|
$19.8M |
| 3 |
Elevance Health
ELV
|
$11.2M |
| 4 |
Molina Healthcare
MOH
|
$11.2M |
| 5 |
DexCom
DXCM
|
$10.6M |
Top Sells
| 1 |
Merck
MRK
|
$21.9M |
| 2 |
Inspire Medical Systems
INSP
|
$21.4M |
| 3 |
Cigna
CI
|
$16.5M |
| 4 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$14.7M |
| 5 |
Boston Scientific
BSX
|
$14.5M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Oscar Health
OSCR
$4.57B
| $13.4M | 1.54% |
1,022,743
-339,678
| -25% | -$4.45M |
|
27
Alnylam Pharmaceuticals
ALNY
$58.6B
| $13M | 1.5% |
48,197
+31,197
| +184% | +$8.42M |
|
28
Royalty Pharma
RPRX
$15.8B
| $12.8M | 1.47% |
411,000
-184,000
| -31% | -$5.73M |
|
29
Axsome Therapeutics
AXSM
$6.09B
| $12.8M | 1.47% |
109,600
-13,000
| -11% | -$1.52M |
|
30
Humana
HUM
$37.5B
| $12.4M | 1.42% |
46,830
-8,400
| -15% | -$2.22M |
|
|
31
DexCom
DXCM
$30.9B
| $10.6M | 1.22% |
+155,000
| New | +$10.6M |
|
32
Neurocrine Biosciences
NBIX
$13.5B
| $9.93M | 1.14% |
89,817
-10,500
| -10% | -$1.16M |
|
33
Zimmer Biomet
ZBH
$20.8B
| $9.87M | 1.14% |
87,250
-36,750
| -30% | -$4.16M |
|
|
34
Cigna
CI
$80.2B
| $9.28M | 1.07% |
28,200
-50,185
| -64% | -$16.5M |
|
35
Cencora
COR
$57.2B
| $9M | 1.03% |
32,375
-21,375
| -40% | -$5.94M |
|
36
Danaher
DHR
$143B
| $8.6M | 0.99% |
41,952
-22,000
| -34% | -$4.51M |
|
37
Centene
CNC
$14.8B
| $7.65M | 0.88% |
126,000
-69,482
| -36% | -$4.22M |
|
38
Dynavax Technologies
DVAX
$1.19B
| $7.33M | 0.84% |
565,000
-274,131
| -33% | -$3.56M |
|
39
TG Therapeutics
TGTX
$5.03B
| $7M | 0.8% |
177,500
-85,000
| -32% | -$3.35M |
|
40
Abbott
ABT
$230B
| $6.9M | 0.79% |
52,000
-76,000
| -59% | -$10.1M |
|
41
Biogen
BIIB
$20.5B
| $6.77M | 0.78% |
49,500
-74,200
| -60% | -$10.2M |
|
42
Align Technology
ALGN
$9.59B
| $6.59M | 0.76% |
41,500
-400
| -1% | -$63.5K |
|
43
Thermo Fisher Scientific
TMO
$183B
| $6.29M | 0.72% |
12,640
-3,000
| -19% | -$1.49M |
|
44
HCA Healthcare
HCA
$95.4B
| $5.8M | 0.67% |
16,778
-17,601
| -51% | -$6.08M |
|
45
Syndax Pharmaceuticals
SNDX
$1.39B
| $5.32M | 0.61% |
433,000
+201,000
| +87% | +$2.47M |
|
|
AVR
46
Anteris Technologies Global Corp. Common Stock
AVR
$148M
| $4.7M | 0.54% |
+1,290,000
| New | +$4.7M |
|
47
Astrana Health
ASTH
$1.42B
| $4.65M | 0.53% |
150,000
+70,000
| +88% | +$2.17M |
|
|
VRNA
48
Verona Pharma
VRNA
$9.18B
| $4.44M | 0.51% |
+70,000
| New | +$4.44M |
|
49
Becton Dickinson
BDX
$54.3B
| $4.35M | 0.5% |
19,000
-28,900
| -60% | -$6.62M |
|
50
Cytokinetics
CYTK
$5.98B
| $4.19M | 0.48% |
104,250
-45,000
| -30% | -$1.81M |
|